Novartis wins FDA green light for new Exjade formulation; Amneal buys Actavis Australia's generics biz;

@FiercePharma: ICYMI earlier: $GSK finally seals U.K. Bexsero deal for £20 per dose. FierceVaccines story | Follow @FiercePharma

@EricPFierce: ICYMI last week from FiercePharmaManufacturing: IPCA says FDA bans will have little sales impact. Didn't Wockhardt make that claim before its profits sank? More | Follow @EricPFierce

@CarlyHFierce: New fantasy: An Invokana/Vimizim final. Tell me that doesn't sound like a Halloween dream come true. Make it happen, people. | Follow @CarlyHFierce

> The FDA has approved Novartis' ($NVS) Jadenu, a new formulation of Exjade, for iron chelation. Release

> Amneal Pharmaceuticals has announced a deal to acquire the generics business of Actavis Australia. More

> Actavis ($ACT) is set to save about €750,000 on energy bills, helping the company substantially cut its production costs. Report

> Novartis' Zykadia has cleared the first step in the U.K.'s early access scheme. More

> Teva ($TEVA) has launched a generic of Novartis' high-blood-pressure med Exforge in the U.S. Release

Medical Device News

@FierceMedDev: Medical device cybersecurity expert says better 'cybersecurity hygiene' needed. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI: Philips brings in former Hologic CEO to head imaging biz in ongoing HealthTech revamp. Article | Follow @StacyALawrence

@VarunSaxena2: Japanese researchers study carbon nanotubes with drug delivery applications. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: $PHG sold its lighting business for $2.8B. Bloomberg article | Follow @EmilyWFierce

> VA starts trial of mobile app to help manage PTSD symptoms. Story

> Philips sells LED, automotive lighting for almost $3B, readies to reinvest in HealthTech. Article

> Olympus settles accounting scandal as it struggles to address duodenoscope difficulties. Report

Biotech News

@FierceBiotech: Skincare startup bags $50M to get its acne drug into Phase III. Article | Follow @FierceBiotech

@JohnCFierce: Merck ties up with tiny Syndax on a 'breakthrough' cancer combo. News | Follow @JohnCFierce

@DamianFierce: This could be the lingering effects of watching Going Clear, but doesn't Jadenu sound like an evil space lord? Novartis' release | Follow @DamianFierce

> GlaxoSmithKline leads a $21M round for PhII kidney drug developer Thrasos. Story

> Aegerion reaches a cease-fire with its activist agitators. Article

> Fujifilm bags stem cell pioneer Cellular Dynamics in $307M buyout. Report

Drug Delivery News

> Genisphere boasts preclinical success of 3DNA platform for cataract complications. Report

> Columbia Labs picks up multidrug intravaginal ring created at MIT and MGH. More

> Researchers convert microbubbles to even smaller nanobubbles using ultrasound. Item

> Japanese researchers studying carbon nanotubes with drug delivery applications. Story

> Novan receives $50M in support of drug delivery tech to treat acne, HPV. Article

Pharma Manufacturing News

> Mylan recalling two injectable drugs made in India. Report

> Federal authorities raid Internet pharmacy operator CanadaDrugs.com. More

> Fujifilm expands in U.S. again with deal for stem cell producer. Story

> Roche's Genentech investing $125M in Oregon plant. News

> Sanofi vaccine plant in Canada again producing ImmuCyst bladder drug. Article

Pharma Asia News

> Japan pharma market on track for $80B mark by 2020, but obstacles seen. News

> Indian company says compulsory license use has cost country $10B in potential investments. Report

> China puts stem-cell clinical trial regulation in play with draft for comment. More

> 'Japanese NIH' launches April 1 with focus on devices and drugs. Story

> Chi-Med's fruquintinib meets metastatic colorectal cancer Phase II primary endpoint. Article

And Finally... The largest association of U.S. pharmacists has approved a measure calling on members to avoid participating in executions. Report

Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.